Abstract
We studied a nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimen for the treatment of children infected with NRTI-resistant HIV-1. The combination of lopinavir/ritonavir and efavirenz suppressed HIV-1 levels for a prolonged period and resulted in a significant increase in CD4+ T cell numbers despite an extensive prior treatment with NRTI (>4 years). Observed side effects were transient with the exception of dyslipidaemia.
Publication types
-
Clinical Trial
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Alkynes
-
Antiretroviral Therapy, Highly Active*
-
Benzoxazines
-
Child
-
Child, Preschool
-
Cyclopropanes
-
Drug Therapy, Combination
-
HIV Infections / drug therapy*
-
HIV Infections / virology
-
HIV-1 / drug effects
-
Humans
-
Lopinavir
-
Oxazines / adverse effects
-
Oxazines / therapeutic use*
-
Pyrimidinones / adverse effects
-
Pyrimidinones / therapeutic use*
-
Reverse Transcriptase Inhibitors / adverse effects
-
Reverse Transcriptase Inhibitors / therapeutic use*
-
Ritonavir / adverse effects
-
Ritonavir / therapeutic use*
-
Treatment Outcome
Substances
-
Alkynes
-
Benzoxazines
-
Cyclopropanes
-
Oxazines
-
Pyrimidinones
-
Reverse Transcriptase Inhibitors
-
Lopinavir
-
efavirenz
-
Ritonavir